Cell Line Development Market Overview

Cell Line Development Market share report has valued the industry size at USD 2.85 billion in 2021 and is projected to grow from USD 3.13 Billion in 2022 to USD 6.15 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 10.10% during the forecast period (2022 - 2030). 

Primary Boosters and Challenges

Several biopharma vendors make extensive use of cells, which work as expression hosts for the production of recombinant monoclonal antibodies. The mounting need for monoclonal antibodies and effective cancer therapeutics, along with the emergence and use of cutting-edge techniques for novel cell line production has resulted in considerable revenue generation in recent years. Moreover, surging focus on developing biosimilars due to patent expiry of established therapeutics and recombinant proteins will further push the market demand.

Disconcerting rise in chronic diseases across the world has fostered the need for efficient and innovative treatment solutions, leading to significant requirement for biosimilars, vaccines, proteins, and novel drugs. This is touted to create favorable avenues for the global market, in terms of revenues over the ensuing years. Several risks associated with cell line development, such as random alternations, contamination, and misidentification, can act as growth impediments for the global market in subsequent years.

On the bright side, the mounting utilization of regenerative medicine, surge in healthcare expenditure, and substantial investments in the biotechnology industry should also benefit the global market in the next few years. Within the biotechnology sector, drug discovery, gene therapy, and cell culture are some of the major applications of cell line development and will be responsible for strong product demand in the following years.

COVID-19 Analysis

COVID-19 has had a disastrous impact on the healthcare sector, as numerous production facilities forced to shut down and product demand plummeting rapidly. With healthcare’s focus mostly on finding SARS-CoV-2 vaccine, other areas had to take a backseat.

Having said that, it is expected that with operations across the globe resuming and the lockdowns being lifted up, the global cell line development industry can again gain significant traction in the coming period. Also, since the biopharmaceutical sector is emerging as a major end-user, and is increasingly using cell line development techniques, it is presumed that the global market will note sustained growth throughout the evaluation period.

Market Segmentation

Type, product, source, and application have been covered in the report as major segments, to present a detailed outline of the cell line development industry.

Different types of cell lines are Primary cell, Hybridoma Cell Line, Continuous Cell Line, and Recombinant Cell Line. Primary cell line is on track to be the fastest-progressing segment over the years ahead, considering its rising applications in cell metabolism, cell morphology, and genetics.

Products considered are Media and Reagents as well as Equipment. Media and reagents category has taken the leading place in the market, in view of the surging adoption of these products for cell line development.

Source-based market segments include Mammalian cells, non-Mammalian cells and others.

Major applications covered in the MRFR study are Tissue Engineering, Drug Discovery, Bioproduction, and more. The leading spot belongs to the bioproduction segment, on account of cell lines’ rising use in bioproduction, accelerated number of antibiotics, along with vaccine production.

Regional Status  

The biggest gainer out of all the regions is North America, wherein the cell line development market is thriving backed by the mounting need for effective therapeutics to detect cancer as well as auto immune disorders. Escalating use of modern techniques for bioproduction also add to the market worth in the region. Widely known vendors based in the region are focused on product innovations and also enter into partnerships and collaborations to up their business prospects. Some of these companies are Sigma-Aldrich Corporation (US), Thermo Fisher Scientific Inc. (US), and American Type Culture Collection (ATCC), to name a few.l

Eminent Firms

The key participants listed in the MRFR's Cell Line Development Market outlook report are Selexis SA (Switzerland), Lonza Group AG (Switzerland), American Type Culture Collection (ATCC) (US.), Thermo Fisher Scientific, Inc. (US.), Sigma-Aldrich Corporation (U.S.), GE Healthcare (US.), Corning, Inc. (US.), Promega Corporation (US), WuXiAppTec, Inc. (China), Sartorious AG (Germany), and many more.

These players strive to widen their global presence while focusing on coming up with highly advanced products via numerous strategies like collaborations, and partnerships.

About Market Research Future:

Market Research Future (MRFR) is a global market research company that takes pride in its services, offering a complete and accurate analysis with regard to diverse markets and consumers worldwide. Market Research Future has the distinguished objective of providing the optimal quality research and granular research to clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help answer your most important questions.

Contact Us:

Market Research Future (Part of Wantstats Research and Media Private Limited)

99 Hudson Street, 5Th Floor

New York, NY 10013

United States of America

+1 628 258 0071 (US)

+44 2035 002 764 (UK)

Email: sales@marketresearchfuture.com

Website: https://www.marketresearchfuture.com